Tirzepatide in the Treatment of Cannabis Use Disorder
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: addiction
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; BMI ≥22 required; non-obese participants included; conditions: Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe
- Interventions
- Tirzepatide
- Conditions
- Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe
- Phase and size
- Phase 3 · 15 participants
- Dates
- Start 2026-08-01
Primary completion 2028-07-31 - Sponsor
- McMaster University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Tolerability of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder.From baseline to 12-week endpoint.
- Feasibility of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder.From baseline to 12-week endpoint.
02Eligibility
Who can take part
Inclusion Criteria: * Adults aged 18 and above * DSM-5 Cannabis Use Disorder diagnosis of at least moderate severity (4+ DSM-5 symptoms) * 4 or more days of cannabis use per week * Treatment seeking * A Body Mass Index (BMI) ≥ 22 Exclusion Criteria: * Meet DSM-5 criteria for Cluster A or B personality disorders and/or unstable current bipolar disorder, schizophrenia, or psychotic disorder * Comorbid severe DSM-5 Major Depressive Disorder * Present a serious suicide risk or who are likely to require psychiatric hospitalization during the course of the study, as determined by the study physician and Columbia Suicide Severity Rating Scale * Any other mental health condition deemed incompatible by the study team * Meet DSM-5 criteria for alcohol or substance use disorder for any substance other than cannabis or tobacco in the past 6 months * Positive urine drug screen for any substance except cannabis * Concurrent addiction-focused psychotherapy in the past 6 months * Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months * A personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 * Current unstable medical condition * A lifetime diagnosis of Diabetes * Females who are pregnant/nursing, or individuals in reproductive age who do not consent to using birth control during the study * Concomitant treatment with: other GLP-1 agonists, Contrave, bupropion, naltrexone, acamprosate within the past year. No lifetime treatment with tirzepatide. * Significant literacy, visual, or hearing problems * Co-enrollment in a clinical drug trial
03Change log
Registry changes
No changes recorded since the trial was added.